login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
RECURSION PHARMACEUTICALS-A (RXRX) Stock News
USA
-
Nasdaq
- NASDAQ:RXRX -
US75629V1044
-
Common Stock
4.44
USD
-0.24 (-5.13%)
Last: 12/18/2025, 8:00:02 PM
4.5
USD
+0.06 (+1.35%)
After Hours:
12/18/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
RXRX Latest News, Press Relases and Analysis
All
Press Releases
a day ago - By: The Motley Fool
- Mentions:
JPM
Why Recursion Pharmaceuticals Stock Vaulted 11% Higher on Wednesday
a day ago - By: Benzinga
- Mentions:
JPM
Recursion Pharmaceuticals Stock Is Soaring Today: Here's Why
2 days ago - By: Stocktwits
- Mentions:
SPY
ORCL
HUT
PCSA
...
Oracle, Hut 8, Processa Pharmaceuticals, Recursion Pharmaceuticals, Udemy: Stocks Making The Biggest Moves Today
a month ago - By: Benzinga
- Mentions:
TECH
INSE
GEF
SKYT
...
Earnings Scheduled For November 5, 2025
2 months ago - By: The Motley Fool
Recursion Pharmaceuticals (RXRX) CEO Sells 100,000 Shares
11 days ago - By: Recursion Pharmaceuticals, Inc.
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
11 days ago - By: Recursion Pharmaceuticals, Inc.
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
14 days ago - By: Zacks Investment Research
- Mentions:
KRYS
Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue?
18 days ago - By: Recursion Pharmaceuticals
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025
18 days ago - By: Recursion Pharmaceuticals
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025
a month ago - By: MarketNewsUpdates.com
- Mentions:
AVAI
NTLA
ZYME
ANVS
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
a month ago - By: Zacks Investment Research
- Mentions:
IVVD
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates
a month ago - By: Recursion Pharmaceuticals
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update
a month ago - By: Recursion Pharmaceuticals
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update
a month ago - By: Recursion Pharmaceuticals
Recursion Announces CEO Transition Plan to Drive Next Phase of Growth
a month ago - By: Recursion Pharmaceuticals
Recursion Announces CEO Transition Plan to Drive Next Phase of Growth
a month ago - By: Recursion Pharmaceuticals
Recursion to Participate in Upcoming Investor Conferences
2 months ago - By: Zacks Investment Research
- Mentions:
ANIP
CRSP
IMCR
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?
2 months ago - By: Zacks Investment Research
- Mentions:
NAGE
Earnings Preview: Recursion Pharmaceuticals (RXRX) Q3 Earnings Expected to Decline
2 months ago - By: Recursion Pharmaceuticals
Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th
2 months ago - By: Recursion Pharmaceuticals
Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th
Please enable JavaScript to continue using this application.